Dr Jen-Yu (Amy) Chang
BSc (Pharm), MSc (ClinPharm), PhD
School of Medicine and Population Health
Research Fellow in Statistics
Full contact details
School of Medicine and Population Health
Regent Court (ScHARR)
30 Regent Street
Sheffield
S1 4DA
- Profile
-
I joined SCHARR as a staff member after completing my PhD here, where I specialised in treatment sequences in health economic evaluations and the incorporation of advanced causal inference methods. My research focuses on applying these techniques—such as Target Trial Emulation and g-methods—to generate real-world evidence on the comparative effectiveness of treatment sequences using secondary databases. My research addresses the challenges in evaluating treatment sequences within HTA due to the lack of clinical evidence, as trials typically do not compare treatment sequences. Importantly, merging evidence from different treatment lines of trials requires making population exchangeability assumptions, which may not always hold.
Prior to my PhD, I obtained a BSc and an MSc in Pharmacy/Clinical Pharmacy, during which I developed a cost-effectiveness model that informed the national reimbursement of a pharmacist-led anticoagulation service in Taiwan. I then worked in an academic role with consultancy responsibilities, supporting local HTA submissions for pharmaceutical companies by adapting oncology economic models and generating local evidence using national claims data. Alongside this core responsibility, I contributed to the construction of the Taiwan EQ-5D-5L tariff model and healthcare utilisation and pharmacoepidemiology studies using Taiwan national health insurance claims and US NHIS survey data. Additionally, I worked as a pharmacist from time to time.
- Research interests
-
My current research interests lie in health economic modelling and related research methodologies with an emphasis on the comparison of treatment sequences. From a wider perspective, I am interested in applying causal inference methods and using real-world data to inform economic evaluation.
I am an active learner and keen on having exposure to innovative analytical methods and interdisciplinary research.
- Publications
-
Show: Featured publications All publications
Featured publications
This person does not have any publications available.
All publications
Journal articles
- Challenges and opportunities in interdisciplinary research and real-world data for treatment sequences in health technology assessments. PharmacoEconomics, 42(5), 487-506. View this article in WRRO
- Beyond 10-year lead-times in EQ-5D-5L: leveraging alternative lead-times in willingness-to-accept questions to capture preferences for worse-than-dead states and their implication. The European Journal of Health Economics, 25(6), 1041-1055.
- The role of response domain and scale label in the quantitative interpretation of patient-reported outcome measure response options. Quality of Life Research, 30(7), 2097-2108. View this article in WRRO
- Influenza Vaccination Among Pregnant Women in the United States: Findings from the 2012–2016 National Health Interview Survey. Journal of Women's Health, 28(7), 965-975.
- Valuation of the EQ-5D-5L in Taiwan. PLoS ONE, 13(12). View this article in WRRO
- Cost-effectiveness of the pharmacist-assisted warfarin monitoring program at a Medical Center in Taiwan. International Journal for Quality in Health Care, 29(6), 817-825.
Conference proceedings papers
- MSR64 Enhanced Randomised Controlled Trials-Real-World Evidence (RCT-RWE) Agreement Assessment Metrics for Health Technology Assessment (HTA). Value in Health, Vol. 27(12) (pp S450-S450)
- RWD66 Application of the target trial framework for estimating comparative effectiveness using real-world data-a systematic review.. Value in Health, Vol. 25(12 Suppl) (pp S461). Vienna, Austria, 6 November 2022 - 6 November 2022. View this article in WRRO
- 26th Annual Conference of the International Society for Quality
of Life Research. Quality of Life Research, Vol. 28(S1) (pp 1-190)
- The role of context and label in participants' quantitative interpretation of common quality of life PROM response options. QUALITY OF LIFE RESEARCH, Vol. 28 (pp S136-S137)
- EQ-5D-5L Valuation Study in Taiwan. Value in Health, Vol. 21 (pp S91-S91)
- Using Hybrid Interval Regression Approach to Examine the Impact of Extending the Standard 10-Year Leading Time in Composite Time-Trade-Off Exercises in Taiwan EQ-5D-5L Valuation Study. Value in Health, Vol. 21 (pp S89-S89)
- Influenza Vaccination Among Pregnant Women: Exploratory Analysis From The 2012-2015 National Health Interview Survey. Value in Health, Vol. 20(9) (pp A797-A797)
- Changes In Treatment Patterns Of Tyrosine Kinase Inhibitors Among Non-Small Cell Lung Cancer Patients Under The National Health Insurance In Taiwan. Value in Health, Vol. 20(9) (pp A463-A464)
- Cost-Effectiveness of the Pharmacist-Assisted Warfarin Monitoring Program (PAWM) at a Medical Center in Taiwan. Value in Health, Vol. 19(7) (pp A612-A613)
- Challenges and opportunities in interdisciplinary research and real-world data for treatment sequences in health technology assessments. PharmacoEconomics, 42(5), 487-506. View this article in WRRO
- Research group
-
SCHARR-TAG:
PhD Supervisors:
Professor Jim Chilcott
- Teaching interests
-
I currently support the survival analysis component in R for HAR6178: Further Statistical Methods for Health Economic Analysis. I've led tutorials for an MBChB module on medical research design and the critical appraisal of RCTs and systematic reviews. I’ve also served as a peer mentor for new PhD students.